Leveraging Type I Interferons: Exploring Pathogenesis and Therapeutic Strategies in Autoimmune Diseases

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Type I interferons (IFN-I) play a critical role in immune responses, including antiviral activity and tumor suppression.
• Aberrant IFN-I signaling and gene expression are linked to the onset, clinical features, and severity of autoimmune diseases.
• Type I interferonopathies, monogenic disorders of the IFN-I pathway, share characteristics with systemic lupus erythematosus (SLE).

Purpose of the Study:

• To review the intricate relationship between epigenetics, RNA molecules, transcription factors, and Type I interferons (IFN-I).
• To explore the role of epigenetic modifications and transcription factor dysregulation in the context of IFN-I and autoimmune diseases.
• To provide insights into disease mechanisms and potential future therapeutic strategies targeting the IFN-I pathway.

Main Methods:

• Literature review focusing on epigenetics, RNA, transcription factors, and Type I interferons.
• Analysis of preclinical models and clinical trial data related to IFN-I signaling pathway modulation.
• Synthesis of information on genetic mutations, gene expression, and clinical manifestations in autoimmune conditions.

Main Results:

• IFN-I dysregulation is a significant factor in the pathogenesis and progression of autoimmune disorders.
• Epigenetic modifications and transcription factor abnormalities contribute to altered IFN-I activity.
• Targeting the IFN-I signaling pathway shows promise in preclinical and clinical settings for autoimmune disease treatment.

Conclusions:

• The interplay of epigenetics, RNA, and transcription factors with IFN-I is central to autoimmune disease mechanisms.
• Further research into these interactions can illuminate novel therapeutic targets for autoimmune conditions.
• Modulating the IFN-I pathway represents a promising strategy for managing autoimmune diseases.